<DOC>
	<DOCNO>NCT00433043</DOCNO>
	<brief_summary>Many heart failure patient unable reach target beta blocker dose . This study address whether cardiac resynchronization therapy ( CRT ) enable uptitration beta-blockers target dose whether favorably affect remodel reduce leave ventricular end systolic volume ( LVESV ) , measurable clinical benefit , beyond CRT alone ( without change beta-blocker dose ) .</brief_summary>
	<brief_title>BOAT : Beta Blocker Uptitration With OptiVol After Cardiac Resynchronization Therapy ( CRT )</brief_title>
	<detailed_description>Beta blocker proven benefit heart failure ( HF ) patient regard morbidity mortality . However , initiation uptitration remain challenge many patient . Worsening heart failure , symptomatic hypotension symptomatic bradycardia limit up-titration target dos show mortality benefit ( carvedilol [ Coreg ] 25 mg bid , metoprolol succinate [ Toprol-XL ] 200 mg qd ) large clinical trial ( COPERNICUS , MERIT-HF ) . It debate whether benefit beta-blockade solely due heart rate reduction broadly cardiac , central peripheral effect block sympathetic activity . Clearly , remodel effect dilate ventricle . Furthermore , patient heart rate 64 bpm less rarely begin beta-blocker therapy . It know whether patient give pacemaker order safely initiate beta-blocker therapy . It also clear isolate right ventricular pace deleterious effect ventricular dyssynchrony symptomatic heart failure despite medical therapy . Biventricular pacing ( BIVPM ) , also know cardiac resynchronization therapy ( CRT ) , pace mode choice patient wide QRS complex symptomatic HF . It hypothesize CRT therapy allow increase Beta -blocker dose ( initiation beta-blocker patient previously intolerant ) improve NYHA , ejection fraction , remodel effect . The synergy two establish heart failure therapy require evaluation prospective randomize trial .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<criteria>NYHA IIIIV QRS &gt; 120 msec On medical therapy , beta blocker dose @ target ( carvedilol 25 bid , metoprolol succinate 200 qd ) QRS &lt; 120 msec On target beta blocker dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Beta blocker</keyword>
	<keyword>Resynchronization</keyword>
	<keyword>Congestive Heart Failure , NYHA III-IV</keyword>
	<keyword>Candidate BIVPM</keyword>
	<keyword>Not Target Dose ( Coreg 25 Bid Toprol XL 200 qd )</keyword>
</DOC>